ASP0739
Phase 1/2Terminated 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer
Conditions
Ovarian Cancer, NSCLC, ESCC, Solid Tumors
Trial Timeline
Dec 23, 2021 → Jun 1, 2023
NCT ID
NCT04939701About ASP0739
ASP0739 is a phase 1/2 stage product being developed by Astellas Pharma for Ovarian Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04939701. Target conditions include Ovarian Cancer, NSCLC, ESCC.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04939701 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Ovarian Cancer